Different responses to gefitinib in lung adenocarcinoma coexpressing mutant- and wild-type epidermal growth factor receptor genes

被引：9

作者：

Chou, Wen-Chi

Huang, Shiu-Feng

Yeh, Kun-Yang

Wang, Hung-Ming

Liu, Mei-Ying

Hsieh, Jia-Juan

Cheung, Yun-Chung

Chang, John Wen-Cheng

机构：

[1] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Dept Hematol, Tao Yuan, Taiwan

[2] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Dept Oncol, Tao Yuan, Taiwan

[3] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Dept Diagnost Radiol 1, Tao Yuan, Taiwan

[4] Natl Hlth Res Inst, Div Mol & Genom Med, Miaoli, Taiwan

[5] Pahai Hosp, Dept Hematol & Oncol, Yilan, Taiwan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 36卷 / 08期

关键词：

lung cancer (diagnosis & staging; translational oncology; gene profiling; signal transduction; EGFR mutation);

D O I：

10.1093/jjco/hyl057

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Response to gefitinib is strongly associated with the status of the epidermal growth factor receptor gene. Here we report the different treatment responses in a case of lung adenocarcinoma coexpressing mutant-type gene in the primary lung mass and a wild-type gene in the metastatic bone lesions. This case demonstrated that at least two strains of tumor cells were present in a single patient. This may be one of the mechanisms of gefitinib resistance.

引用

页码：523 / 526

页数：4

共 24 条

[1]

[Anonymous], 2003, Lung Cancer

[2] Critical update and emerging trends in epidermal growth factor receptor targeting in cancer [J].

Baselga, J ;

Arteaga, CL .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2445-2459

[3] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

[4]

GATZEMEIER U, 2004, P ASCO

[5] Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1 [J].

Giaccone, G ;

Herbst, RS ;

Manegold, C ;

Scagliotti, G ;

Rosell, R ;

Miller, V ;

Natale, RB ;

Schiller, JH ;

von Pawel, J ;

Pluzanska, A ;

Gatzemeier, M ;

Grous, J ;

Ochs, JS ;

Averbuch, SD ;

Wolf, MK ;

Rennie, P ;

Fandi, A ;

Johnson, DH .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :777-784

[6] Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib [J].

Han, SW ;

Kim, TY ;

Hwang, PG ;

Jeong, S ;

Kim, J ;

Choi, IS ;

Oh, DY ;

Kim, LH ;

Kim, DW ;

Chung, DH ;

Im, SA ;

Kim, YT ;

Lee, JS ;

Heo, DS ;

Bang, YJ ;

Kim, NK .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2493-2501

[7] Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2 [J].

Herbst, RS ;

Giaccone, G ;

Schiller, JH ;

Natale, RB ;

Miller, V .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :785-794

[8]

HERBST RS, 2004, P ASCO

[9] High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan [J].

Huang, SF ;

Liu, HP ;

Li, LH ;

Ku, YC ;

Fu, YN ;

Tsai, HY ;

Chen, YT ;

Lin, YF ;

Chang, WC ;

Kuo, HP ;

Wu, YC ;

Chen, YR ;

Tsai, SF .

CLINICAL CANCER RESEARCH, 2004, 10 (24) :8195-8203

[10] The conformational plasticity of protein kinases [J].

Huse, M ;

Kuriyan, J .

CELL, 2002, 109 (03) :275-282

← 1 2 3 →